These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2179764)

  • 1. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation.
    Kastrukoff LF; Oger JJ; Hashimoto SA; Sacks SL; Li DK; Palmer MR; Koopmans RA; Petkau AJ; Berkowitz J; Paty DW
    Neurology; 1990 Mar; 40(3 Pt 1):479-86. PubMed ID: 2179764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation.
    Kastrukoff LF; Oger JJ; Tourtellotte WW; Sacks SL; Berkowitz J; Paty DW
    Neurology; 1991 Dec; 41(12):1936-41. PubMed ID: 1745353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of magnetic resonance imaging in monitoring interferon therapy of multiple sclerosis.
    Koopmans RA; Li DK; Redekop WK; Zhao GJ; Palmer MR; Kastrukoff LF; Paty DW
    J Neuroimaging; 1993 Jul; 3(3):163-8. PubMed ID: 10146223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.
    Myhr KM; Riise T; Green Lilleås FE; Beiske TG; Celius EG; Edland A; Jensen D; Larsen JP; Nilsen R; Nortvedt MW; Smievoll AI; Vedeler C; Nyland HI
    Neurology; 1999 Mar; 52(5):1049-56. PubMed ID: 10102427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):566-74. PubMed ID: 2659737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.
    Hirsch RL; Johnson KP; Camenga DL
    Int J Neurosci; 1988 Apr; 39(3-4):189-96. PubMed ID: 3045033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH
    Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
    Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
    Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
    Sørensen PS; Sellebjerg F; Lycke J; Färkkilä M; Créange A; Lund CG; Schluep M; Frederiksen JL; Stenager E; Pfleger C; Garde E; Kinnunen E; Marhardt K;
    Eur J Neurol; 2016 May; 23(5):861-70. PubMed ID: 26848561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
    Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis.
    Rostami AM; Sater RA; Bird SJ; Galetta S; Farber RE; Kamoun M; Silberberg DH; Grossman RI; Pfohl D
    Mult Scler; 1999 Jun; 5(3):198-203. PubMed ID: 10408721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
    Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.